533 related articles for article (PubMed ID: 33765691)
1. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD004434. PubMed ID: 23450552
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
[TBL] [Abstract][Full Text] [Related]
5. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
7. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
8. Guanylate cyclase stimulators for pulmonary hypertension.
Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
12. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
More K; Athalye-Jape GK; Rao SC; Patole SK
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010531. PubMed ID: 27535894
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
Kuntz M; Leiva-Juarez MM; Luthra S
Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
16. Exercise-based rehabilitation programmes for pulmonary hypertension.
Morris NR; Kermeen FD; Jones AW; Lee JY; Holland AE
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD011285. PubMed ID: 36947725
[TBL] [Abstract][Full Text] [Related]
17. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
18. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
19. Beta-blockers for hypertension.
Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]